Advertisement

Topics

Generic Therapy Launched for Metastatic NSCLC and Pancreatic Cancer

11:44 EDT 10 May 2019 | Pharmacy Times

Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

Original Article: Generic Therapy Launched for Metastatic NSCLC and Pancreatic Cancer

NEXT ARTICLE

More From BioPortfolio on "Generic Therapy Launched for Metastatic NSCLC and Pancreatic Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...